Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

STADA Arzneimittel AG adjusts FY 2014 outlook


Monday, 24 Mar 2014 09:01am EDT 

STADA Arzneimittel AG:No longer expects to completely achieve outlook for 2014 as published in context of a long-term prognosis in 2010.Expects however slight growth in group sales, adjusted EBITDA and adjusted net income in FY 2014.For reasons of transparency, adjustments as from 2014 to also include negative currency effects from devaluation of Russian ruble as well as further currencies of market region CIS/Eastern Europe.FY 2013 group sales of 2,014.4 million euros, FY 2013 adjusted EBITDA 415.2 million euros and FY 2013 adjusted net income of 160.6 million euros.FY 2014 revenue estimate 2,168 million euros, FY 2014 EBITDA estimate 440.77 million euros, FY 2014 net income estimate 197.10 million euros - Thomson Reuters I/B/E/S. 

Company Quote

25.115
0.48 +1.95%
3:19am EST